The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients : A Multicenter Cohort Study
The use of erythropoietin-stimulating agents (ESAs) as adjunctive therapy in critically ill patients with COVID-19 may have a potential benefit. This study aims to evaluate the effect of ESAs on the clinical outcomes of critically ill COVID-19 patients. A multicenter, retrospective cohort study was conducted from 01-03-2020 to 31-07-2021. We included adult patients who were ≥ 18 years old with a confirmed diagnosis of COVID-19 infection and admitted to intensive care units (ICUs). Patients were categorized depending on ESAs administration during their ICU stay. The primary endpoint was the length of stay; other endpoints were considered secondary. After propensity score matching (1:3), the overall included patients were 120. Among those, 30 patients received ESAs. A longer duration of ICU and hospital stay was observed in the ESA group (beta coefficient: 0.64; 95% CI: 0.31-0.97; P = < .01, beta coefficient: 0.41; 95% CI: 0.12-0.69; P = < .01, respectively). In addition, the ESA group's ventilator-free days (VFDs) were significantly shorter than the control group. Moreover, patients who received ESAs have higher odds of liver injury and infections during ICU stay than the control group. The use of ESAs in COVID-19 critically ill patients was associated with longer hospital and ICU stays, with no survival benefits but linked with lower VFDs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis - 29(2023) vom: 10. Jan., Seite 10760296231218216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al Sulaiman, Khalid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 11.12.2023 published: Print Citation Status In-Process |
|---|
| doi: |
10.1177/10760296231218216 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365638692 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365638692 | ||
| 003 | DE-627 | ||
| 005 | 20231229123256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/10760296231218216 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1227.xml |
| 035 | |a (DE-627)NLM365638692 | ||
| 035 | |a (NLM)38073058 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al Sulaiman, Khalid |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients |b A Multicenter Cohort Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status In-Process | ||
| 520 | |a The use of erythropoietin-stimulating agents (ESAs) as adjunctive therapy in critically ill patients with COVID-19 may have a potential benefit. This study aims to evaluate the effect of ESAs on the clinical outcomes of critically ill COVID-19 patients. A multicenter, retrospective cohort study was conducted from 01-03-2020 to 31-07-2021. We included adult patients who were ≥ 18 years old with a confirmed diagnosis of COVID-19 infection and admitted to intensive care units (ICUs). Patients were categorized depending on ESAs administration during their ICU stay. The primary endpoint was the length of stay; other endpoints were considered secondary. After propensity score matching (1:3), the overall included patients were 120. Among those, 30 patients received ESAs. A longer duration of ICU and hospital stay was observed in the ESA group (beta coefficient: 0.64; 95% CI: 0.31-0.97; P = < .01, beta coefficient: 0.41; 95% CI: 0.12-0.69; P = < .01, respectively). In addition, the ESA group's ventilator-free days (VFDs) were significantly shorter than the control group. Moreover, patients who received ESAs have higher odds of liver injury and infections during ICU stay than the control group. The use of ESAs in COVID-19 critically ill patients was associated with longer hospital and ICU stays, with no survival benefits but linked with lower VFDs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ESA | |
| 650 | 4 | |a critically ill | |
| 650 | 4 | |a erythropoietin-stimulating agents | |
| 650 | 4 | |a length of stay | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a ventilator-free days (VFDs) | |
| 700 | 1 | |a Aljuhani, Ohoud |e verfasserin |4 aut | |
| 700 | 1 | |a Korayem, Ghazwa B |e verfasserin |4 aut | |
| 700 | 1 | |a Altebainawi, Ali F |e verfasserin |4 aut | |
| 700 | 1 | |a Vishwakarma, Ramesh |e verfasserin |4 aut | |
| 700 | 1 | |a AlFaifi, Mashael |e verfasserin |4 aut | |
| 700 | 1 | |a Alsohimi, Samiah |e verfasserin |4 aut | |
| 700 | 1 | |a Alrayes, Aljoharah |e verfasserin |4 aut | |
| 700 | 1 | |a Albishi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Reem |e verfasserin |4 aut | |
| 700 | 1 | |a Alalawi, Mai |e verfasserin |4 aut | |
| 700 | 1 | |a Al Sulaihim, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Alanazi, Thamer A |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Rahaf A |e verfasserin |4 aut | |
| 700 | 1 | |a Almagthali, Alaa |e verfasserin |4 aut | |
| 700 | 1 | |a Jomah, Shahamah |e verfasserin |4 aut | |
| 700 | 1 | |a Alshlowi, Areej |e verfasserin |4 aut | |
| 700 | 1 | |a Alshammari, Tahani R |e verfasserin |4 aut | |
| 700 | 1 | |a Alzahrani, Shahad S |e verfasserin |4 aut | |
| 700 | 1 | |a Abdulqader, Marwa I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis |d 1998 |g 29(2023) vom: 10. Jan., Seite 10760296231218216 |w (DE-627)NLM094498261 |x 1938-2723 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g day:10 |g month:01 |g pages:10760296231218216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/10760296231218216 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |b 10 |c 01 |h 10760296231218216 | ||